Usually a combination of an aromatase inhibitor (or fulvestrant) and a CDK4/6 inhibitor (such as palbociclib, ribociclib, or abemaciclib).
Treatment decisions are primarily driven by the tumor's biological profile, specifically Hormone Receptor (HR) and HER2 status. HR-Positive, HER2-Negative (Luminal) Download Traitement cancer sein mГ©tastatique pdf
Metastatic breast cancer (MBC) treatment has undergone a significant shift in 2026, moving from generic protocols toward precision medicine tailored to specific tumor subtypes and genetic mutations. While MBC remains a chronic condition requiring lifelong management rather than a curable one, modern therapeutic strategies aim to maximize survival and maintain high quality of life. Current Standards of Care (2026) Usually a combination of an aromatase inhibitor (or
As of early 2026, the European Commission approved inavolisib (Itovebi) for use in combination with palbociclib and fulvestrant for advanced forms of the disease. While MBC remains a chronic condition requiring lifelong